Citations

Clear

229 citation(s) found for "Chow, W".

Mammalian Pitrilysin: Substrate Specificity and Mitochondrial Targeting
Chow, K. Martin, Gakh, Oleksandr , Payne, I. C., Juliano, María A. , Juliano, Luiz , Isaya, Grazia , Hersh, Louis B.

Mayo Clinic

Biochemistry | February 7, 2009 | Volume: 48 | Issue: 13 | Pages: 2868-2877

10.1021/bi8016125 | PMID 19196155 Get It

Rebuttal
Chow, George K.

Mayo Clinic

Journal of Endourology | October 2, 2008 | Volume: 22 | Issue: 9 | Pages: 2095-2096

10.1089/end.2008.9738a Get It

Ureteroscopic Treatment of Pelvic Renal Tumor in a Solitary Kidney with Orthotopic Neobladder
Chow, George K.

Mayo Clinic

Journal of Endourology | October 2, 2008 | Volume: 22 | Issue: 9 | Pages: 2091-2092

10.1089/end.2008.9738 | PMID 18811552 Get It

Cyproheptadine displays preclinical activity in myeloma and leukemia
Mao, Xinliang , Liang, Sheng-Ben, Hurren, Rose, Gronda, Marcela, Chow, Sue, Xu, Gang , Zavareh, Reza Beheshti , Jamal, Nazir, Messner, Hans A., Hedley, David W. , Datti, Alessandro , Wrana, Jeffrey L. , Zhu, Yuanxiao, Shi, Chang-Xin, Tiedemann, Rodger E. , Trudel, Suzanne , Stewart, A. Keith , Schimmer, Aaron D. , Liang, Sheng‐Ben , Wang, Xiaoming , Lee, Kyle

Mayo Clinic

Blood | May 24, 2008 | Volume: 112 | Issue: 3 | Pages: 760-769

10.1182/blood-2008-02-142687 | PMID 18502826 Get It

AbstractD-cyclins are regulators of cell division that act in a complex with cyclin-dependent kinases to commit cells to a program of DNA replication. D-cyclins are overexpressed in many tumors, including multiple myeloma and leukemia, and contribute to disease progression and chemoresistance. To better understand the role and impact of D-cyclins in hematologic malignancies, we conducted a high throughput screen for inhibitors of the cyclin D2 promoter and identified the drug cyproheptadine. In myeloma and leukemia cells, cyproheptadine decreased expression of cyclins D1, D2, and D3 and arrested these cells in the G0/G1 phase. After D-cyclin suppression, cyproheptadine induced apoptosis in myeloma and leukemia cell lines and primary patient samples preferentially over normal hematopoietic cells. In mouse models of myeloma and leukemia, cyproheptadine inhibited tumor growth without significant toxicity. Cyproheptadine-induced apoptosis was preceded by activation of the mitochondrial pathway of caspase activation and was independent of the drug's known activity as an H1 histamine and serotonin receptor antagonist. Thus, cyproheptadine represents a lead for a novel therapeutic agent for the treatment of malignancy. Because the drug is well tolerated and already approved in multiple countries for clinical use as an antihistamine and appetite stimulant, it could be moved directly into clinical trials for cancer.
Abdominal Aortic Calcification, BMD, and Bone Microstructure: A Population-Based Study
Chow, John T., Khosla, Sundeep , Melton, L. Joseph, Atkinson, Elizabeth J. , Camp, Jon J. , Kearns, Ann E. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | May 8, 2008 | Volume: 23 | Issue: 10 | Pages: 1601-1612

10.1359/jbmr.080504 | PMID 18466072 Get It

Abstract To better define the relationship between vascular calcification and bone mass/structure, we assessed abdominal aortic calcification (AAC), BMD, and bone microstructure in an age-stratified, random sample of 693 Rochester, MN, residents. Participants underwent QCT of the spine and hip and high-resolution pQCT (HRpQCT) of the radius to define volumetric BMD (vBMD) and microstructural parameters. AAC was quantified with the Agatston scoring method. In men, AAC correlated with lower vertebral trabecular and femoral neck vBMD (p < 0.001), but not after age or multivariable (age, body mass index, smoking status) adjustment. Separation into <50 and ≥50 yr showed this pattern only in the older men. BV/TV and Tb.Th inversely correlated with AAC in all men (p < 0.001), and Tb.Th remained significantly correlated after age adjustment (p < 0.05). Tb.N positively correlated with AAC in younger men (p < 0.001) but negatively correlated in older men (p < 0.001). The opposite was true with Tb.Sp (p = 0.01 and p < 0.001, respectively). Lower Tb.N and higher Tb.Sp correlated with AAC in older men even after multivariable adjustment. Among all women and postmenopausal women, AAC correlated with lower vertebral and femoral neck vBMD (p < 0.001) but not after adjustment. Lower BV/TV and Tb.Th correlated with AAC (p = 0.03 and p = 0.04, respectively) in women, but not after adjustment. Our findings support an age-dependent association between AAC and vBMD. We also found that AAC correlates with specific bone microstructural parameters in older men, suggesting a possible common pathogenesis for vascular calcification and deterioration in bone structure. However, sex-specific differences exist.
Percutaneous Renal Cryoablation: Experience Treating 115 Tumors
Atwell, Thomas D. , Farrell, Michael A., Leibovich, Bradley C. , Callstrom, Matthew R. , Chow, George K. , Blute, Michael L., Charboneau, J. William

Mayo Clinic

Journal of Urology | April 18, 2008 | Volume: 179 | Issue: 6 | Pages: 2136-2141

10.1016/j.juro.2008.01.144 | PMID 18423719 Get It

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Adjei, Alex A. , Cohen, Roger B. , Franklin, Wilbur A., Morris, Clive, Wilson, David M. , Molina, Julian R. , Hanson, Lorelei J., Gore, Lia , Maloney, Lara , Gordon, Gilad S., Simmons, Heidi, Marlow, Allison, Litwiler, Kevin , Brown, Suzy, Pöch, G, Kane, Katie, Haney, Jerry, Chow, Laura Q.M. , Leong, Stephen , Eckhardt, Sabine

Mayo Clinic

Journal of Clinical Oncology | April 8, 2008 | Volume: 26 | Issue: 13 | Pages: 2139-2146

10.1200/jco.2007.14.4956 | PMID 18390968 Get It

Purpose To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. Patients and Methods In part A, patients received escalating doses to determine the maximum-tolerated dose (MTD). In both parts, blood samples were collected to assess PK and PD parameters. In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to receive the MTD or 50% MTD. Biopsies were collected to determine inhibition of ERK phosphorylation, Ki-67 expression, and BRAF, KRAS, and NRAS mutations. Results Fifty-seven patients were enrolled. MTD in part A was 200 mg bid, but this dose was discontinued in part B because of toxicity. The 50% MTD (100 mg bid) was well tolerated. Rash was the most frequent and dose-limiting toxicity. Most other adverse events were grade 1 or 2. The PKs were less than dose proportional, with a median half-life of approximately 8 hours and inhibition of ERK phosphorylation in peripheral-blood mononuclear cells at all dose levels. Paired tumor biopsies demonstrated reduced ERK phosphorylation (geometric mean, 79%). Five of 20 patients demonstrated ≥ 50% inhibition of Ki-67 expression, and RAF or RAS mutations were detected in 10 of 26 assessable tumor samples. Nine patients had stable disease (SD) for ≥ 5 months, including two patients with SD for 19 (thyroid cancer) and 22 (uveal melanoma plus renal cancer) 28-day cycles. Conclusion AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose. PK analyses supported twice-daily dosing. Prolonged SD was seen in a variety of advanced cancers. Phase II studies are ongoing.
Asian Indians Have Enhanced Skeletal Muscle Mitochondrial Capacity to Produce ATP in Association With Severe Insulin Resistance
Bigelow, Maureen L., Asmann, Yan W. , Chow, Lisa S. , Coenen-Schimke, Jill M., Klaus, Katherine A. , Guo, ZengKui, Raghavakaimal, Sreekumar, Irving, Brian A. , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | February 19, 2008 | Volume: 57 | Issue: 5 | Pages: 1166-1175

10.2337/db07-1556 | PMID 18285554 Get It

OBJECTIVE— Type 2 diabetes has become a global epidemic, and Asian Indians have a higher susceptibility to diabetes than Europeans. We investigated whether Indians had any metabolic differences compared with Northern European Americans that may render them more susceptible to diabetes. RESEARCH DESIGN AND METHODS— We studied 13 diabetic Indians, 13 nondiabetic Indians, and 13 nondiabetic Northern European Americans who were matched for age, BMI, and sex. The primary comparisons were insulin sensitivity by hyperinsulinemic-euglycemic clamp and skeletal muscle mitochondrial capacity for oxidative phosphorylation (OXPHOS) by measuring mitochondrial DNA copy number (mtDNA), OXPHOS gene transcripts, citrate synthase activity, and maximal mitochondrial ATP production rate (MAPR). Other factors that may cause insulin resistance were also measured. RESULTS— The glucose infusion rates required to maintain identical glucose levels during the similar insulin infusion rates were substantially lower in diabetic Indians than in the nondiabetic participants (P < 0.001), and they were lower in nondiabetic Indians than in nondiabetic Northern European Americans (P < 0.002). mtDNA (P < 0.02), OXPHOS gene transcripts (P < 0.01), citrate synthase, and MAPR (P < 0.03) were higher in Indians irrespective of their diabetic status. Intramuscular triglyceride, C-reactive protein, interleukin-6, and tumor necrosis factor-α concentrations were higher, whereas adiponectin concentrations were lower in diabetic Indians. CONCLUSIONS— Despite being more insulin resistant, diabetic Indians had similar muscle OXPHOS capacity as nondiabetic Indians, demonstrating that diabetes per se does not cause mitochondrial dysfunction. Indians irrespective of their diabetic status had higher OXPHOS capacity than Northern European Americans, although Indians were substantially more insulin resistant, indicating a dissociation between mitochondrial dysfunction and insulin resistance.
Surgery for Cushing’s Syndrome: An Historical Review and Recent Ten‐year Experience
Porterfield, John R. , Thompson, Geoffrey B. , Chow, John T., Fryrear, Raymond, Heerden, Jon A. van, Farley, David R. , Atkinson, John L. D., Meyer, Fredric B. , Abboud, Charles F., Nippoldt, Todd B., Natt, Neena, Erickson, Dana , Carpenter, Paul C., Richards, Melanie L. , Carney, J. Aidan, Larson, Dirk, Schleck, Cathy D. , Churchward, Marilyn, Grant, Clive S., Young, William F. , Vella, Adrian

Mayo Clinic

World Journal of Surgery | January 14, 2008 | Volume: 32 | Issue: 5 | Pages: 659-677

10.1007/s00268-007-9387-6 | PMID 18196319 Get It

AbstractBackgroundCushing’s syndrome (CS), due to multiple etiologies, is a disorder associated with the ravages of cortisol excess. The purpose of this review article is to provide a historical synopsis of surgery for CS, review a recent 10‐year period of operative management at a tertiary care facility, and to outline a practical approach to diagnosis and management.Materials and MethodsFrom 1996 to 2005, 298 patients underwent 322 operative procedures for CS at Mayo Clinic, Rochester, Minnesota. A retrospective chart review was carried out. Data was gathered regarding demographics, preoperative assessment, procedures performed, and outcomes. Data are presented as counts and percentages. Five‐year survival rates were calculated where applicable by the Kaplan‐Meier method. Statistical analysis was carried out with SAS, version 9 (SAS Institute, Inc., Cary, NC).ResultsTwo‐hundred thirty‐one patients (78%) had ACTH‐dependent CS and 67 patients (22%) had ACTH‐independent CS. One‐hundred ninety‐six patients (66%) had pituitary‐dependent CS and 35 patients (12%) had ectopic ACTH syndrome. Fifty‐four patients (18%) had cortisol‐secreting adenomas, 10 patients (3%) had cortisol‐producing adrenocortical carcinomas, and 1% had other causes. Cure rates for first time pituitary operations (transsphenoidal, sublabial, and endonasal) were 80% and 55% for reoperations. Most benign adrenal processes could be managed laparoscopically. Five‐year survival rates (all causes) were 90%, 51%, and 23% for adrenocortical adenomas, ectopic ACTH syndrome, and adrenocortical carcinomas, respectively.ConclusionsSurgery for CS is highly successful for pituitary‐dependent CS and most ACTH‐independent adrenal causes. Bilateral total adrenalectomy can also provide effective palliation from the ravages of hypercortisolism in patients with ectopic ACTH syndrome and for those who have failed transsphenoidal surgery. Unfortunately, to date, adrenocortical carcinomas are rarely cured. Future successes with this disease will likely depend on a better understanding of tumor biology, more effective adjuvant therapies and earlier detection. Clearly, IPSS, advances in cross‐sectional imaging, along with developments in transsphenoidal and laparoscopic surgery, have had the greatest impact on today’s management of the complex patient with CS.
Potential Underdetection of pT 3a Renal-Cell Carcinoma with Laparoscopic Morcellation
Granberg, Candace F. , Krambeck, Amy E. , Leibovich, Bradley C. , Frank, Igor, Lohse, Christine M. , Gettman, Matthew T., Blute, Michael L., Chow, George C.

Mayo Clinic

Journal of Endourology | October 21, 2007 | Volume: 21 | Issue: 10 | Pages: 1183-1186

10.1089/end.2007.9910 | PMID 17949322 Get It